Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Meta-Analysis of Grazoprevir plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection.

Annals of hepatology - 1 Jan 2000

Ahmed Hussien, Abushouk Abdelrahman Ibrahim, Menshawy Amr, Attia Attia, Mohamed Arwa, Negida Ahmed, Abdel-Daim Mohamed M

Abstract excerpt

BACKGROUND AND AIM: Grazoprevir is an NS3/4A protease inhibitor (PI), while elbasvir is an NS5A inhibitor. We performed this meta-analysis to directly compare grazoprevir plus elbasvir and ribavirin regimen vs. grazoprevir and elbasvir without ribavirin in the treatment of hepatitis C virus genotype 1 infection and to precisely evaluate the efficacy of the latter regimen in cirrhotic, IL28 CC genotype patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzofurans
Share to Drug Combinations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Quinoxalines

Share to Randomized Controlled Trials as Topic

Share to Ribavirin

Share to Sustained Virologic Response

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 29311409
DOI: 10.5604/01.3001.0010.7532

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Meta-Analysis of Grazoprevir plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection.PMID 29311409Read ↗

Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis.Semantic proximity Read ↗

Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.Semantic proximity Read ↗

Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial.Semantic proximity Read ↗

Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4.Semantic proximity Read ↗

Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.Semantic proximity Read ↗

Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis.Semantic proximity Read ↗

The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.Semantic proximity Read ↗

Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis.Semantic proximity Read ↗

Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C.Semantic proximity Read ↗

Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.Semantic proximity Read ↗

Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.Semantic proximity Read ↗

Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.